Advertisement

Neurosarcoidosis

  • Michael J. Bradshaw
  • Siddharama Pawate
  • Jeffrey A. SparksEmail author
Chapter

Abstract

The protean manifestations of neurosarcoidosis (NS) make familiarity with its clinical, radiological, and biological spectra important for the astute clinician. A rational approach to the diagnosis and a thorough knowledge of the differential diagnosis is critical. No clinical trials in NS have been conducted to date, but treatment with glucocorticoids and steroid-sparing immunosuppressive agents is appropriate. Recent advances in management of NS include the use of tumor necrosis factor (TNF) inhibitors for aggressive or refractory cases.

Keywords

Neurosarcoidosis Sarcoidosis Cranial neuropathy Meningitis Myelitis Granuloma Tumor necrosis factor TNF inhibitors Glucocorticoids 

References

  1. 1.
    Hunninghake GW, Costabel U, Ando M, Baughman R, Cordier JF, du Bois R, et al. ATS/ERS/WASOG statement on sarcoidosis. American thoracic society/European respiratory society/world association of sarcoidosis and other granulomatous disorders. Sarcoidosis Vasc Diffuse Lung Dis. 1999;16(2):149–73.PubMedGoogle Scholar
  2. 2.
    Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med. 2007;357(21):2153–65.PubMedCrossRefGoogle Scholar
  3. 3.
    Rybicki BA, Iannuzzi MC. Epidemiology of sarcoidosis: recent advances and future prospects. Semin Respir Crit Care Med. 2007;28(1):22–35.PubMedCrossRefGoogle Scholar
  4. 4.
    Bagnato F, Stern BJ. Neurosarcoidosis: diagnosis, therapy and biomarkers. Expert Rev Neurother. 2015;15(5):533–48.PubMedCrossRefGoogle Scholar
  5. 5.
    Iwai K, Tachibana T, Takemura T, Matsui Y, Kitaichi M, Kawabata Y. Pathological studies on sarcoidosis autopsy. I. Epidemiological features of 320 cases in Japan. Acta Pathol Jpn. 1993;43(7–8):372–6.PubMedGoogle Scholar
  6. 6.
    Stern BJ, Krumholz A, Johns C, Scott P, Nissim J. Sarcoidosis and its neurological manifestations. Arch Neurol. 1985;42(9):909–17.PubMedCrossRefGoogle Scholar
  7. 7.
    Krumholz A, Stern BJ. Neurologic manifestations of sarcoidosis. In: Handbook of clinical neurology, vol. 119; 2014. p. 305–33.Google Scholar
  8. 8.
    Oksanen V. Neurosarcoidosis: clinical presentations and course in 50 patients. Acta Neurol Scand. 1986;73(3):283–90.PubMedCrossRefGoogle Scholar
  9. 9.
    Zajicek JP, Scolding NJ, Foster O, Rovaris M, Evanson J, Moseley IF, et al. Central nervous system sarcoidosis–diagnosis and management. QJM. 1999;92(2):103–17.PubMedCrossRefGoogle Scholar
  10. 10.
    Scott TF, Yandora K, Valeri A, Chieffe C, Schramke C. Aggressive therapy for neurosarcoidosis: long-term follow-up of 48 treated patients. Arch Neurol. 2007;64(5):691–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Ferriby D, de Seze J, Stojkovic T, Hachulla E, Wallaert B, Destee A, et al. Long-term follow-up of neurosarcoidosis. Neurology. 2001;57(5):927–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Carlson ML, White JR Jr, Espahbodi M, Haynes DS, Driscoll CL, Aksamit AJ, et al. Cranial base manifestations of neurosarcoidosis: a review of 305 patients. Otol Neurotol: official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology. 2015;36(1):156–66.Google Scholar
  13. 13.
    Tavee JO, Stern BJ. Neurosarcoidosis. Clin Chest Med. 2015;36(4):643–56.PubMedCrossRefGoogle Scholar
  14. 14.
    Pawate S, Moses H, Sriram S. Presentations and outcomes of neurosarcoidosis: a study of 54 cases. QJM. 2009;102(7):449–60.PubMedCrossRefGoogle Scholar
  15. 15.
    Hoitsma E, Faber CG, Drent M, Sharma OP. Neurosarcoidosis: a clinical dilemma. Lancet Neurol. 2004;3(7):397–407.PubMedCrossRefGoogle Scholar
  16. 16.
    Terushkin V, Stern BJ, Judson MA, Hagiwara M, Pramanik B, Sanchez M, et al. Neurosarcoidosis: presentations and management. Neurologist. 2010;16(1):2–15.PubMedCrossRefGoogle Scholar
  17. 17.
    Hickman SJ. Optic perineuritis. Curr Neurol Neurosci Rep. 2016;16(2):16.PubMedCrossRefGoogle Scholar
  18. 18.
    Luke RA, Stern BJ, Krumholz A, Johns CJ. Neurosarcoidosis: the long-term clinical course. Neurology. 1987;37(3):461–3.PubMedCrossRefGoogle Scholar
  19. 19.
    Colvin IB. Audiovestibular manifestations of sarcoidosis: a review of the literature. Laryngoscope. 2006;116(1):75–82.PubMedCrossRefGoogle Scholar
  20. 20.
    Murialdo G, Tamagno G. Endocrine aspects of neurosarcoidosis. J Endocrinol Investig. 2002;25(7):650–62.CrossRefGoogle Scholar
  21. 21.
    Nowak DA, Widenka DC. Neurosarcoidosis: a review of its intracranial manifestation. J Neurol. 2001;248(5):363–72.PubMedCrossRefGoogle Scholar
  22. 22.
    Lury KM, Smith JK, Matheus MG, Castillo M. Neurosarcoidosis–review of imaging findings. Semin Roentgenol. 2004;39(4):495–504.PubMedCrossRefGoogle Scholar
  23. 23.
    Macedo PJ, da Silveira VC, Ramos LT, Nobrega FR, Vasconcellos LF. Isolated central nervous system vasculitis as a manifestation of neurosarcoidosis. J Stroke Cerebrovasc Dis. 2016;25(6):e89–92.PubMedCrossRefGoogle Scholar
  24. 24.
    Brown MM, Thompson AJ, Wedzicha JA, Swash M. Sarcoidosis presenting with stroke. Stroke. 1989;20(3):400–5.PubMedCrossRefGoogle Scholar
  25. 25.
    Spiegel DR, Morris K, Rayamajhi U. Neurosarcoidosis and the complexity in its differential diagnoses: a review. Innov Clin Neurosci. 2012;9(4):10–6.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Ginat DT, Dhillon G, Almast J. Magnetic resonance imaging of neurosarcoidosis. J Clin Imaging Sci. 2011;1:15.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Joubert B, Chapelon-Abric C, Biard L, Saadoun D, Demeret S, Dormont D, et al. Association of prognostic factors and immunosuppressive treatment with long-term outcomes in neurosarcoidosis. JAMA Neurol. 2017;74(11):1336–44.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Junger SS, Stern BJ, Levine SR, Sipos E, Marti-Masso JF. Intramedullary spinal sarcoidosis: clinical and magnetic resonance imaging characteristics. Neurology. 1993;43(2):333–7.PubMedCrossRefGoogle Scholar
  29. 29.
    Hashmi M, Kyritsis AP. Diagnosis and treatment of intramedullary spinal cord sarcoidosis. J Neurol. 1998;245(3):178–80.PubMedCrossRefGoogle Scholar
  30. 30.
    Smith JK, Matheus MG, Castillo M. Imaging manifestations of neurosarcoidosis. AJR Am J Roentgenol. 2004;182(2):289–95.PubMedCrossRefGoogle Scholar
  31. 31.
    Flanagan EP, Kaufmann TJ, Krecke KN, Aksamit AJ, Pittock SJ, Keegan BM, et al. Discriminating long myelitis of neuromyelitis optica from sarcoidosis. Ann Neurol. 2016;79(3):437–47.PubMedCrossRefGoogle Scholar
  32. 32.
    Zalewski NL, Krecke KN, Weinshenker BG, Aksamit AJ, Conway BL, McKeon A, et al. Central canal enhancement and the trident sign in spinal cord sarcoidosis. Neurology. 2016;87(7):743–4.PubMedCrossRefGoogle Scholar
  33. 33.
    Zuniga G, Ropper AH, Frank J. Sarcoid peripheral neuropathy. Neurology. 1991;41(10):1558–61.PubMedCrossRefGoogle Scholar
  34. 34.
    Burns TM, Dyck PJ, Aksamit AJ, Dyck PJ. The natural history and long-term outcome of 57 limb sarcoidosis neuropathy cases. J Neurol Sci. 2006;244(1–2):77–87.PubMedCrossRefGoogle Scholar
  35. 35.
    Vital A, Lagueny A, Ferrer X, Louiset P, Canron MH, Vital C. Sarcoid neuropathy: clinico-pathological study of 4 new cases and review of the literature. Clin Neuropathol. 2008;27(2):96–105.PubMedCrossRefGoogle Scholar
  36. 36.
    Heij L, Dahan A, Hoitsma E. Sarcoidosis and pain caused by small-fiber neuropathy. Pain Res Treat. 2012;2012:256024.PubMedPubMedCentralGoogle Scholar
  37. 37.
    Wong JC, Sparks JA, Doyle TJ, Paulson VA, Milligan TA, Prasad S. Systemic sarcoidosis presenting as harlequin and horner syndrome. Neurol Clin Pract. 2015;5(6):524–7.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Tavee J, Culver D. Sarcoidosis and small-fiber neuropathy. Curr Pain Headache Rep. 2011;15(3):201–6.PubMedCrossRefGoogle Scholar
  39. 39.
    Ungprasert P, Carmona EM, Crowson CS, Matteson EL. Diagnostic utility of angiotensin-converting enzyme in sarcoidosis: a population-based study. Lung. 2016;194(1):91–5.PubMedCrossRefGoogle Scholar
  40. 40.
    Bridel C, Courvoisier DS, Vuilleumier N, Lalive PH. Cerebrospinal fluid angiotensin-converting enzyme for diagnosis of neurosarcoidosis. J Neuroimmunol. 2015;285:1–3.PubMedCrossRefGoogle Scholar
  41. 41.
    Lexa FJ, Grossman RI. MR of sarcoidosis in the head and spine: spectrum of manifestations and radiographic response to steroid therapy. AJNR Am J Neuroradiol. 1994;15(5):973–82.PubMedGoogle Scholar
  42. 42.
    Bathla G, Singh AK, Policeni B, Agarwal A, Case B. Imaging of neurosarcoidosis: common, uncommon, and rare. Clin Radiol. 2016;71(1):96–106.PubMedCrossRefGoogle Scholar
  43. 43.
    Teirstein AS, Machac J, Almeida O, Lu P, Padilla ML, Iannuzzi MC. Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis. Chest. 2007;132(6):1949–53.PubMedCrossRefGoogle Scholar
  44. 44.
    Rossi G, Cavazza A, Colby TV. Pathology of sarcoidosis. Clin Rev Allergy Immunol. 2015;49(1):36–44.PubMedCrossRefGoogle Scholar
  45. 45.
    Nakajima T, Yasufuku K, Fujiwara T, Yoshino I. Recent advances in endobronchial ultrasound-guided transbronchial needle aspiration. Respir Investig. 2016;54(4):230–6.PubMedCrossRefGoogle Scholar
  46. 46.
    Agbogu BN, Stern BJ, Sewell C, Yang G. Therapeutic considerations in patients with refractory neurosarcoidosis. Arch Neurol. 1995;52(9):875–9.PubMedCrossRefGoogle Scholar
  47. 47.
    Stern BJ, Aksamit A, Clifford D, Scott TF, Neurosarcoidosis Study G. Neurologic presentations of sarcoidosis. Neurol Clin. 2010;28(1):185–98.PubMedCrossRefGoogle Scholar
  48. 48.
    Fritz D, van de Beek D, Brouwer MC. Clinical features, treatment and outcome in neurosarcoidosis: systematic review and meta-analysis. BMC Neurol. 2016;16(1):220.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Nozaki K, Judson MA. Neurosarcoidosis. Curr Treat Options Neurol. 2013;15(4):492–504.PubMedCrossRefGoogle Scholar
  50. 50.
    Lorentzen AO, Sveberg L, Midtvedt O, Kerty E, Heuser K. Overnight response to infliximab in neurosarcoidosis: a case report and review of infliximab treatment practice. Clin Neuropharmacol. 2014;37(5):142–8.PubMedCrossRefGoogle Scholar
  51. 51.
    Riancho-Zarrabeitia L, Delgado-Alvarado M, Riancho J, Oterino A, Sedano MJ, Rueda-Gotor J, et al. Anti-TNF-alpha therapy in the management of severe neurosarcoidosis: a report of five cases from a single centre and literature review. Clin Exp Rheumatol. 2014;32(2):275–84.PubMedGoogle Scholar
  52. 52.
    Lower EE, Broderick JP, Brott TG, Baughman RP. Diagnosis and management of neurological sarcoidosis. Arch Intern Med. 1997;157(16):1864–8.PubMedCrossRefGoogle Scholar
  53. 53.
    Androdias G, Maillet D, Marignier R, Pinede L, Confavreux C, Broussolle C, et al. Mycophenolate mofetil may be effective in CNS sarcoidosis but not in sarcoid myopathy. Neurology. 2011;76(13):1168–72.PubMedCrossRefGoogle Scholar
  54. 54.
    Sharma OP. Effectiveness of chloroquine and hydroxychloroquine in treating selected patients with sarcoidosis with neurological involvement. Arch Neurol. 1998;55(9):1248–54.PubMedCrossRefGoogle Scholar
  55. 55.
    Bitoun S, Bouvry D, Borie R, Mahevas M, Sacre K, Haroche J, et al. Treatment of neurosarcoidosis: a comparative study of methotrexate and mycophenolate mofetil. Neurology. 2016;87(24):2517–21.PubMedCrossRefGoogle Scholar
  56. 56.
    Iannuzzi MC, Fontana JR. Sarcoidosis: clinical presentation, immunopathogenesis, and therapeutics. JAMA. 2011;305(4):391–9.PubMedCrossRefGoogle Scholar
  57. 57.
    Baughman RP, Lower EE. Treatment of sarcoidosis. Clin Rev Allergy Immunol. 2015;49(1):79–92.PubMedCrossRefGoogle Scholar
  58. 58.
    Marnane M, Lynch T, Scott J, Stack J, Kelly PJ. Steroid-unresponsive neurosarcoidosis successfully treated with adalimumab. J Neurol. 2009;256(1):139–40.PubMedCrossRefGoogle Scholar
  59. 59.
    Decock A, Van Assche G, Vermeire S, Wuyts W, Ferrante M. Sarcoidosis-like lesions: another paradoxical reaction to anti-TNF therapy? J Crohns Colitis. 2016;11(3):378–83.Google Scholar
  60. 60.
    Baughman RP, Drent M, Kavuru M, Judson MA, Costabel U, du Bois R, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med. 2006;174(7):795–802.PubMedCrossRefGoogle Scholar
  61. 61.
    Rossman MD, Newman LS, Baughman RP, Teirstein A, Weinberger SE, Miller W Jr, et al. A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2006;23(3):201–8.PubMedGoogle Scholar
  62. 62.
    Bradshaw MJGJ, Stern B, Clifford DB, Wang Y, Cho TA, Vu N, Sriram S, Moses H, Bagnato F, Koth LL, Hauser SL, Dierkhising J, Kaufmann JA, Ammah D, Yohannes TH, Hamblin MJ, Venna N, Green AJ, Pawate S. Infliximab for the treatment of neurosarcoidosis: a multi-institutional case series. Neurology. 2017;88(16):Supplement P1.335.Google Scholar
  63. 63.
    Gelfand JM, Bradshaw MJ, Stern BJ, Clifford DB, Wang Y, Cho TA, et al. Infliximab for the treatment of CNS sarcoidosis: a multi-institutional series. Neurology. 2017;89:2092.PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    Bradshaw MJ, Mobley BC, Zwerner JP, Sriram S. Autopsy-proven demyelination associated with infliximab treatment. Neurol Neuroimmunol Neuroinflamm. 2016;2016:3(2).Google Scholar
  65. 65.
    Cathcart S, Sami N, Elewski B. Sarcoidosis as an adverse effect of tumor necrosis factor inhibitors. J Drugs Dermatol: JDD. 2012;11(5):609–12.PubMedGoogle Scholar
  66. 66.
    Stern BJ, Royal W, Gelfand J, et al. Definition and Consensus Diagnostic Criteria for Neurosarcoidosis. JAMA Neurol. 2018;75(12):1546-1553.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Michael J. Bradshaw
    • 1
  • Siddharama Pawate
    • 2
  • Jeffrey A. Sparks
    • 3
    • 4
    Email author
  1. 1.Department of NeurologyBillings ClinicBillingsUSA
  2. 2.Department of NeurologyVanderbilt University Medical CenterNashvilleUSA
  3. 3.Department of MedicineHarvard Medical SchoolBostonUSA
  4. 4.Department of Medicine, Division of Rheumatology, Immunology and AllergyBrigham and Women’s HospitalBostonUSA

Personalised recommendations